Insights Into the Serine Protease Mechanism from Atomic Resolution Structures of Trypsin Reaction Intermediates
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Chymotrypsin: a Serine Protease Reaction Mechanism Step
CHEM464/Medh,J.D. Catalytic Strategies Chymotrypsin: A serine protease • Covalent catalysis: temporary covalent modification of reactive • Hydrolyzes peptide bonds on the carboxyl side of group on enzyme active site Tyr, Phe, Trp, Met, Leu • Acid-Base catalysis: A molecule other than water is proton • Since peptide bond is highly unreactive, a strong donor or acceptor (nucleophilic or electrophilic attack) nucleophile is required for its hydrolysis • Metal ion catalysis: Involvement of metal ion in catalysis. A metal ion is an electrophile and (i) may stabilize a negative • Catalytic strategy is covalent modification and charge on an intermediate; (ii) by attracting electrons from acid-base catalysis water, renders water more acidic (prone to loose a proton); (iii) • Contains catalytic triad of Ser, His and Asp. Ser is may bind to substrate and reduce activation energy a nucleophile and participates in covalent • Catalysis by approximation: In reactions requiring more than modification, His is a proton acceptor (base), Asp one substrate, the enzyme facilitates their interaction by serving stabilizes His (and active site) by electrostatic as an adapter that increases proximity of the substrates to each interactions other Reaction Mechanism Step-wise reaction • Hydrolysis by chymotrypsin is a 2-step process • Enzyme active site is stabilized by ionic interactions • Step 1: serine reacts with substrate to form covalent between Asp and His and H-bond between His and Ser. ES complex • In the presence of a substrate, His accepts a proton from • Step 2: release of products from ES complex and Ser, Ser makes a nucleophilic attack on the peptide’s regeneration of enzyme carbonyl C converting its geometry to tetrahedral. -
On the Active Site Thiol of Y-Glutamylcysteine Synthetase
Proc. Natl. Acad. Sci. USA Vol. 85, pp. 2464-2468, April 1988 Biochemistry On the active site thiol of y-glutamylcysteine synthetase: Relationships to catalysis, inhibition, and regulation (glutathione/cystamine/Escherichia coli/kidney/enzyme inactivation) CHIN-SHIou HUANG, WILLIAM R. MOORE, AND ALTON MEISTER Cornell University Medical College, Department of Biochemistry, 1300 York Avenue, New York, NY 10021 Contributed by Alton Meister, December 4, 1987 ABSTRACT y-Glutamylcysteine synthetase (glutamate- dithiothreitol, suggesting that cystamine forms a mixed cysteine ligase; EC 6.3.2.2) was isolated from an Escherichia disulfide between cysteamine and an enzyme thiol (15). coli strain enriched in the gene for this enzyme by recombinant Inactivation of the enzyme by the L- and D-isomers of DNA techniques. The purified enzyme has a specific activity of 3-amino-1-chloro-2-pentanone, as well as that by cystamine, 1860 units/mg and a molecular weight of 56,000. Comparison is prevented by L-glutamate (14). Treatment of the enzyme of the E. coli enzyme with the well-characterized rat kidney with cystamine prevents its interaction with the sulfoxi- enzyme showed that these enzymes have similar catalytic prop- mines. Titration of the enzyme with 5,5'-dithiobis(2- erties (apparent Km values, substrate specificities, turnover nitrobenzoate) reveals that the enzyme has a single exposed numbers). Both enzymes are feedback-inhibited by glutathione thiol that reacts with this reagent without affecting activity but not by y-glutamyl-a-aminobutyrylglycine; the data indicate (16). 5,5'-Dithiobis(2-nitrobenzoate) does not interact with that glutathione binds not only at the glutamate binding site but the thiol that reacts with cystamine. -
Molecular Markers of Serine Protease Evolution
The EMBO Journal Vol. 20 No. 12 pp. 3036±3045, 2001 Molecular markers of serine protease evolution Maxwell M.Krem and Enrico Di Cera1 ment and specialization of the catalytic architecture should correspond to signi®cant evolutionary transitions in the Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Box 8231, St Louis, history of protease clans. Evolutionary markers encoun- MO 63110-1093, USA tered in the sequences contributing to the catalytic apparatus would thus give an account of the history of 1Corresponding author e-mail: [email protected] an enzyme family or clan and provide for comparative analysis with other families and clans. Therefore, the use The evolutionary history of serine proteases can be of sequence markers associated with active site structure accounted for by highly conserved amino acids that generates a model for protease evolution with broad form crucial structural and chemical elements of applicability and potential for extension to other classes of the catalytic apparatus. These residues display non- enzymes. random dichotomies in either amino acid choice or The ®rst report of a sequence marker associated with serine codon usage and serve as discrete markers for active site chemistry was the observation that both AGY tracking changes in the active site environment and and TCN codons were used to encode active site serines in supporting structures. These markers categorize a variety of enzyme families (Brenner, 1988). Since serine proteases of the chymotrypsin-like, subtilisin- AGY®TCN interconversion is an uncommon event, it like and a/b-hydrolase fold clans according to phylo- was reasoned that enzymes within the same family genetic lineages, and indicate the relative ages and utilizing different active site codons belonged to different order of appearance of those lineages. -
(12) Patent Application Publication (10) Pub. No.: US 2016/0346364 A1 BRUNS Et Al
US 2016.0346364A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0346364 A1 BRUNS et al. (43) Pub. Date: Dec. 1, 2016 (54) MEDICAMENT AND METHOD FOR (52) U.S. Cl. TREATING INNATE IMMUNE RESPONSE CPC ........... A61K 38/488 (2013.01); A61K 38/482 DISEASES (2013.01); C12Y 304/23019 (2013.01); C12Y 304/21026 (2013.01); C12Y 304/23018 (71) Applicant: DSM IPASSETS B.V., Heerlen (NL) (2013.01); A61K 9/0053 (2013.01); C12N 9/62 (2013.01); A23L 29/06 (2016.08); A2ID 8/042 (72) Inventors: Maaike Johanna BRUINS, Kaiseraugst (2013.01); A23L 5/25 (2016.08); A23V (CH); Luppo EDENS, Kaiseraugst 2002/00 (2013.01) (CH); Lenneke NAN, Kaiseraugst (CH) (57) ABSTRACT (21) Appl. No.: 15/101,630 This invention relates to a medicament or a dietary Supple (22) PCT Filed: Dec. 11, 2014 ment comprising the Aspergillus niger aspergilloglutamic peptidase that is capable of hydrolyzing plant food allergens, (86). PCT No.: PCT/EP2014/077355 and more particularly, alpha-amylase/trypsin inhibitors, thereby treating diseases due to an innate immune response S 371 (c)(1), in humans, and/or allowing to delay the onset of said (2) Date: Jun. 3, 2016 diseases. The present invention relates to the discovery that (30) Foreign Application Priority Data the Aspergillus niger aspergilloglutamic peptidase is capable of hydrolyzing alpha-amylase/trypsin inhibitors that are Dec. 11, 2013 (EP) .................................. 13196580.8 present in wheat and related cereals said inhibitors being strong inducers of innate immune response. Furthermore, Publication Classification the present invention relates to a method for hydrolyzing alpha-amylase/trypsin inhibitors comprising incubating a (51) Int. -
Crystallography Captures Catalytic Steps in Human Methionine Adenosyltransferase Enzymes
Crystallography captures catalytic steps in human methionine adenosyltransferase enzymes Ben Murraya,b, Svetlana V. Antonyuka, Alberto Marinab, Shelly C. Luc, Jose M. Matod, S. Samar Hasnaina,1, and Adriana L. Rojasb,1 aMolecular Biophysics Group, Institute of Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool L69 7ZX, England; bStructural Biology Unit, Center for Cooperative Research in Biosciences, 48160 Derio, Spain; cDivision of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA 90048; and dCIC bioGUNE, CIBERehd, Parque Tecnologico Bizkaia, 801A-1.48160 Derio, Spain Edited by Gregory A. Petsko, Weill Cornell Medical College, New York, NY, and approved January 8, 2016 (received for review June 4, 2015) The principal methyl donor of the cell, S-adenosylmethionine catalytic mechanism (13, 14) in which the reaction is initiated (SAMe), is produced by the highly conserved family of methionine through a nucleophilic attack by the sulfur atom of methionine adenosyltranferases (MATs) via an ATP-driven process. These en- on the C5′ atom of ATP, which produces the intermediate tri- zymes play an important role in the preservation of life, and their polyphosphate (PPPi). Hydrolysis of the PPPi into pyrophos- dysregulation has been tightly linked to liver and colon cancers. We phate (PPi) and orthophosphate (Pi) then occurs (Fig. S1). present crystal structures of human MATα2 containing various bound A common feature of MAT enzymes is a gating loop that α – ligands, providing a “structural movie” of the catalytic steps. High- to flanks the active site (in human MAT 2 residues 113 131), atomic-resolution structures reveal the structural elements of the which has been postulated to act in a dynamic way to allow ac- enzyme involved in utilization of the substrates methionine and cess to the active site. -
Human Elastase 1: Evidence for Expression in the Skin and the Identi®Cation of a Frequent Frameshift Polymorphism
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Human Elastase 1: Evidence for Expression in the Skin and the Identi®cation of a Frequent Frameshift Polymorphism Ulvi Talas, John Dunlop,1 Sahera Khalaf , Irene M. Leigh, and David P. Kelsell Center for Cutaneous Research, St. Bartholomew's and the Royal London School of Medicine and Dentistry, Whitechapel, London, U.K. Human pancreatic elastase 1 is a serine protease individuals with/without the keratoderma revealed a which maps to the chromosomal region 12q13 close sequence variant, which would result in a premature to a locus for an autosomal dominant skin disease, truncation of the protein. This sequence variant, diffuse nonepidermolytic palmoplantar keratoderma, however, did not segregate with the skin disease and, and was investigated as a possible candidate gene for indeed, was found to occur at a relatively high fre- this disorder. Expression of two elastase inhibitors, quency in the population. Individuals homozygous ela®n and SLPI, has been related to several hyper- for the variant do not have any obvious skin proliferative skin conditions. elastase 1 is functionally abnormalities. Based on the analysis of the secondary silent in the human pancreas but elastase 1 expres- structure of the translated putative protein, the sion at the mRNA level was detected in human truncation is unlikely to result in knock-out of the cultured primary keratinocytes. Antibody staining elastase, but may cause destabilization of the localized the protein to the basal cell layer of the enzyme±inhibitor complex. Key words: ela®n/keratino- human epidermis at a number of sites includingthe cyte/protein truncation/serine protease. -
Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
pharmaceutics Review Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice Malavika Deodhar 1, Sweilem B Al Rihani 1 , Meghan J. Arwood 1, Lucy Darakjian 1, Pamela Dow 1 , Jacques Turgeon 1,2 and Veronique Michaud 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA; [email protected] (M.D.); [email protected] (S.B.A.R.); [email protected] (M.J.A.); [email protected] (L.D.); [email protected] (P.D.); [email protected] (J.T.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +1-856-938-8697 Received: 5 August 2020; Accepted: 31 August 2020; Published: 4 September 2020 Abstract: In an ageing society, polypharmacy has become a major public health and economic issue. Overuse of medications, especially in patients with chronic diseases, carries major health risks. One common consequence of polypharmacy is the increased emergence of adverse drug events, mainly from drug–drug interactions. The majority of currently available drugs are metabolized by CYP450 enzymes. Interactions due to shared CYP450-mediated metabolic pathways for two or more drugs are frequent, especially through reversible or irreversible CYP450 inhibition. The magnitude of these interactions depends on several factors, including varying affinity and concentration of substrates, time delay between the administration of the drugs, and mechanisms of CYP450 inhibition. Various types of CYP450 inhibition (competitive, non-competitive, mechanism-based) have been observed clinically, and interactions of these types require a distinct clinical management strategy. This review focuses on mechanism-based inhibition, which occurs when a substrate forms a reactive intermediate, creating a stable enzyme–intermediate complex that irreversibly reduces enzyme activity. -
Amino Acid Chemistry
Handout 4 Amino Acid and Protein Chemistry ANSC 619 PHYSIOLOGICAL CHEMISTRY OF LIVESTOCK SPECIES Amino Acid Chemistry I. Chemistry of amino acids A. General amino acid structure + HN3- 1. All amino acids are carboxylic acids, i.e., they have a –COOH group at the #1 carbon. 2. All amino acids contain an amino group at the #2 carbon (may amino acids have a second amino group). 3. All amino acids are zwitterions – they contain both positive and negative charges at physiological pH. II. Essential and nonessential amino acids A. Nonessential amino acids: can make the carbon skeleton 1. From glycolysis. 2. From the TCA cycle. B. Nonessential if it can be made from an essential amino acid. 1. Amino acid "sparing". 2. May still be essential under some conditions. C. Essential amino acids 1. Branched chain amino acids (isoleucine, leucine and valine) 2. Lysine 3. Methionine 4. Phenyalanine 5. Threonine 6. Tryptophan 1 Handout 4 Amino Acid and Protein Chemistry D. Essential during rapid growth or for optimal health 1. Arginine 2. Histidine E. Nonessential amino acids 1. Alanine (from pyruvate) 2. Aspartate, asparagine (from oxaloacetate) 3. Cysteine (from serine and methionine) 4. Glutamate, glutamine (from α-ketoglutarate) 5. Glycine (from serine) 6. Proline (from glutamate) 7. Serine (from 3-phosphoglycerate) 8. Tyrosine (from phenylalanine) E. Nonessential and not required for protein synthesis 1. Hydroxyproline (made postranslationally from proline) 2. Hydroxylysine (made postranslationally from lysine) III. Acidic, basic, polar, and hydrophobic amino acids A. Acidic amino acids: amino acids that can donate a hydrogen ion (proton) and thereby decrease pH in an aqueous solution 1. -
Solutions to 7.012 Problem Set 1
MIT Biology Department 7.012: Introductory Biology - Fall 2004 Instructors: Professor Eric Lander, Professor Robert A. Weinberg, Dr. Claudette Gardel Solutions to 7.012 Problem Set 1 Question 1 Bob, a student taking 7.012, looks at a long-standing puddle outside his dorm window. Curious as to what was growing in the cloudy water, he takes a sample to his TA, Brad Student. He wanted to know whether the organisms in the sample were prokaryotic or eukaryotic. a) Give an example of a prokaryotic and a eukaryotic organism. Prokaryotic: Eukaryotic: All bacteria Yeast, fungi, any animial or plant b) Using a light microscope, how could he tell the difference between a prokaryotic organism and a eukaryotic one? The resolution of the light microscope would allow you to see if the cell had a true nucleus or organelles. A cell with a true nucleus and organelles would be eukaryotic. You could also determine size, but that may not be sufficient to establish whether a cell is prokaryotic or eukaryotic. c) What additional differences exist between prokaryotic and eukaryotic organisms? Any answer from above also fine here. In addition, prokaryotic and eukaryotic organisms differ at the DNA level. Eukaryotes have more complex genomes than prokaryotes do. Question 2 A new startup company hires you to help with their product development. Your task is to find a protein that interacts with a polysaccharide. a) You find a large protein that has a single binding site for the polysaccharide cellulose. Which amino acids might you expect to find in the binding pocket of the protein? What is the strongest type of interaction possible between these amino acids and the cellulose? Cellulose is a polymer of glucose and as such has many free hydroxyl groups. -
IL-33 Is Processed Into Mature Bioactive Forms by Neutrophil Elastase and Cathepsin G
IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G Emma Lefrançais, Stephane Roga, Violette Gautier, Anne Gonzalez-de-Peredo, Bernard Monsarrat, Jean-Philippe Girard1,2, and Corinne Cayrol1,2 Centre National de la Recherche Scientifique, Institut de Pharmacologie et de Biologie Structurale, F-31077 Toulouse, France; Université de Toulouse, Université Paul Sabatier, Institut de Pharmacologie et de Biologie Structurale, F-31077 Toulouse, France Edited* by Charles A. Dinarello, University of Colorado Denver, Aurora, CO, and approved December 19, 2011 (received for review October 3, 2011) Interleukin-33 (IL-33) (NF-HEV) is a chromatin-associated nuclear activity (4). However, we (23) and others (24–26) demonstrated cytokine from the IL-1 family, which has been linked to important that full-length IL-33 is biologically active and that processing of diseases, including asthma, rheumatoid arthritis, ulcerative colitis, IL-33 by caspases results in its inactivation, rather than its activa- and cardiovascular diseases. IL-33 signals through the ST2 receptor tion. Further analyses revealed that IL-33 is constitutively and drives cytokine production in type 2 innate lymphoid cells (ILCs) expressed to high levels in the nuclei of endothelial and epithelial (natural helper cells, nuocytes), T-helper (Th)2 lymphocytes, mast cells in vivo (27) and that it can be released in the extracellular cells, basophils, eosinophils, invariant natural killer T (iNKT), and space after cellular damage (23, 24). IL-33 was, thus, proposed (23, natural killer (NK) cells. We and others recently reported that, unlike 24, 27) to function as an endogenous danger signal or alarmin, IL-1β and IL-18, full-length IL-33 is biologically active independently similar to IL-1α and high-mobility group box 1 protein (HMGB1) of caspase-1 cleavage and that processing by caspases results in IL-33 (28–32), to alert cells of the innate immune system of tissue inactivation. -
Spring 2013 Lecture 13-14
CHM333 LECTURE 13 – 14: 2/13 – 15/13 SPRING 2013 Professor Christine Hrycyna INTRODUCTION TO ENZYMES • Enzymes are usually proteins (some RNA) • In general, names end with suffix “ase” • Enzymes are catalysts – increase the rate of a reaction – not consumed by the reaction – act repeatedly to increase the rate of reactions – Enzymes are often very “specific” – promote only 1 particular reaction – Reactants also called “substrates” of enzyme catalyst rate enhancement non-enzymatic (Pd) 102-104 fold enzymatic up to 1020 fold • How much is 1020 fold? catalyst time for reaction yes 1 second no 3 x 1012 years • 3 x 1012 years is 500 times the age of the earth! Carbonic Anhydrase Tissues ! + CO2 +H2O HCO3− +H "Lungs and Kidney 107 rate enhancement Facilitates the transfer of carbon dioxide from tissues to blood and from blood to alveolar air Many enzyme names end in –ase 89 CHM333 LECTURE 13 – 14: 2/13 – 15/13 SPRING 2013 Professor Christine Hrycyna Why Enzymes? • Accelerate and control the rates of vitally important biochemical reactions • Greater reaction specificity • Milder reaction conditions • Capacity for regulation • Enzymes are the agents of metabolic function. • Metabolites have many potential pathways • Enzymes make the desired one most favorable • Enzymes are necessary for life to exist – otherwise reactions would occur too slowly for a metabolizing organis • Enzymes DO NOT change the equilibrium constant of a reaction (accelerates the rates of the forward and reverse reactions equally) • Enzymes DO NOT alter the standard free energy change, (ΔG°) of a reaction 1. ΔG° = amount of energy consumed or liberated in the reaction 2. -
Serine Protease (Chymotrypsin) from Nocardiopsis Prasina Expressed in Bacillus Licheniformis
SERINE PROTEASE (CHYMOTRYPSIN) FROM NOCARDIOPSIS PRASINA EXPRESSED IN BACILLUS LICHENIFORMIS Chemical and Technical Assessment Prepared by Jannavi R. Srinivasan, Ph.D., Reviewed by Dr. Inge Meyland, Ph. D. 1. Summary This Chemical and Technical Assessment (CTA) summarizes data and information on the serine protease with chymotrypsin specificity from Nocardiopsis prasina expressed in Bacillus Licheniformis enzyme preparation submitted to the Joint FAO/WHO Expert Committee on Food Additives (JECFA) by Novozymes A/S in a dossier dated November 25, 2011 (Novozymes, 2011)a. In this CTA, the expression ‘serine protease (chymotrypsin)’ is used when referring to the serine protease with chymotrypsin specificity enzyme and its amino acid sequence, whereas the expression ‘serine protease (chymotrypsin) enzyme preparation’ is used when referring to the enzyme preparation. This document also discusses published information relevant to serine protease (chymotrypsin), the B. licheniformis production organism, and the N. prasina organism that is the source for the serine protease (chymotrypsin) gene. Serine protease (chymotrypsin) catalyses the hydrolysis of peptide bonds in a protein, preferably at the carboxyl end of Tyr (Tyr-X), Phe (Phe-X), Trp (Trp-X), when X is not proline. It also catalyses the hydrolysis of peptide bonds at the carboxyl end of other amino acids, primarily Met and Leu, albeit at a slower rate. It is intended for use in the production of hydrolysed animal and vegetable proteins including casein, whey, soy isolate, soy concentrate, wheat gluten and corn gluten. These hydrolysed proteins will be used for various applications as ingredients in food, protein-fortified food, and beverages. The serine protease (chymotrypsin) enzyme preparation is expected to be inactivated during food processing.